Relapsed or Refractory Ovarian Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Relapsed or refractory ovarian cancer presents a significant medical challenge, and understanding its implications is crucial. Ovarian cancer (OC) ranks the fifth most prevalent cancer in women and is a leading cause of cancer-related mortality, particularly in the 40–79 age group. The prognosis varies significantly depending on the stage of the disease at the time of diagnosis. Around 70% to 80% of OC patients receive their diagnosis at an advanced stage, resulting in a relatively low 5-year survival rate of approximately 29% to 30%. In contrast, those diagnosed in the early stages of the disease experience a significantly better prognosis, with a ten-year survival rate of 90%, compared to a mere 15% for those diagnosed with advanced-stage disease, even with optimal treatment. Despite advancements in treatment options, nearly 70% of ovarian cancer patients experience relapse following primary cytoreductive surgery and standard first-line chemotherapy. Traditionally, treatment strategies have categorized relapse as platinum-sensitive or platinum-resistant/refractory, using somewhat arbitrary definitions. However, these definitions are becoming less relevant with the expanding treatment choices. The current challenge in managing relapsed ovarian cancer lies in determining the most effective sequence of available drugs and the optimal timing for treating relapsed disease.
Thelansis’s “Relapsed or Refractory
Ovarian Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Relapsed or Refractory Ovarian
Cancer treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Relapsed or Refractory Ovarian Cancer across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Relapsed or Refractory Ovarian Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment